PAP
VNDA icon

Persistent Asset Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Persistent Asset Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-530
Closed -$57K – 481
2025
Q4 		$57K Buy
+530
New +$2.92K 0.03% 288

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Persistent Asset Partners's VNDA Position: Q2 2025 in Review

Persistent Asset Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2025, closing a stake of 1,553 shares — an estimated $7.13K sold.

Persistent Asset Partners first reported a position in VNDA in Q1 2025 and held it in 1 quarter. The position peaked at $7.13K in Q1 2025. 139 funds tracked by Wall St. Rank hold VNDA as of Q2 2025.

  • Persistent Asset Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 1,553 Vanda Pharmaceuticals shares in Q2 2025, an estimated $7.13K.
  • Persistent Asset Partners first reported a position in Vanda Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Vanda Pharmaceuticals position peaked at $7.13K in Q1 2025.
  • 139 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2025.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.